- Home
- BMEA vs HOWL Comparison
BMEA vs HOWL Comparison
Compare BMEA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- HOWL
- Stock Information
- Founded
- BMEA 2017
- HOWL 2017
- Country
- BMEA United States
- HOWL United States
- Employees
- BMEA N/A
- HOWL N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- HOWL Health Care
- Exchange
- BMEA Nasdaq
- HOWL Nasdaq
- Market Cap
- BMEA 65.8M
- HOWL 47.1M
- IPO Year
- BMEA 2021
- HOWL 2021
- Fundamental
- Price
- BMEA $1.71
- HOWL $1.27
- Analyst Decision
- BMEA Strong Buy
- HOWL Strong Buy
- Analyst Count
- BMEA 10
- HOWL 3
- Target Price
- BMEA $21.00
- HOWL $8.33
- AVG Volume (30 Days)
- BMEA 1.1M
- HOWL 350.8K
- Earning Date
- BMEA 08-04-2025
- HOWL 08-07-2025
- Dividend Yield
- BMEA N/A
- HOWL N/A
- EPS Growth
- BMEA N/A
- HOWL N/A
- EPS
- BMEA N/A
- HOWL N/A
- Revenue
- BMEA N/A
- HOWL $1,143,000.00
- Revenue This Year
- BMEA N/A
- HOWL N/A
- Revenue Next Year
- BMEA N/A
- HOWL N/A
- P/E Ratio
- BMEA N/A
- HOWL N/A
- Revenue Growth
- BMEA N/A
- HOWL N/A
- 52 Week Low
- BMEA $1.29
- HOWL $0.60
- 52 Week High
- BMEA $13.07
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- BMEA 41.35
- HOWL 53.49
- Support Level
- BMEA $1.65
- HOWL $1.25
- Resistance Level
- BMEA $1.85
- HOWL $1.43
- Average True Range (ATR)
- BMEA 0.11
- HOWL 0.11
- MACD
- BMEA -0.01
- HOWL 0.00
- Stochastic Oscillator
- BMEA 5.56
- HOWL 55.06
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.